NAT Mini-Pool Is West Nile Blood Screen Priority, But IgM Role Is Uncertain
This article was originally published in The Gray Sheet
Executive Summary
FDA is recommending manufacturers of tests that could potentially be used to screen blood for West Nile Virus to pursue nucleic acid test mini-pooling, despite concerns with the procedure's sensitivity
You may also be interested in...
West Nile Screening Is Only First Step To Broader Virus Protection – Panel
FDA hopes that efforts to develop a blood screening assay for West Nile virus will lead to technology that can be adapted to screen for other rare, endemic flaviviruses
CBER Pledges To Create Standards Boosting WNV Screening Development
FDA's Center for Biologics Evaluation & Research will establish performance criteria and standards to facilitate the development of nucleic acid tests (NAT) to screen donated blood for the West Nile virus
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.